Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 9/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394999 | 0.89 | ICMT (0.46) | ICMT | |
| SCHEMBL9890733 | 0.88 | ICMT (0.44) | ICMT | |
| SCHEMBL9890788 | 0.88 | ICMT (0.50) | ICMTSMN1; SMN2 | |
| SCHEMBL9890774 | 0.88 | ICMT (0.54) | ICMTPARP1SLC9A1DCLRE1BHPGDS | |
| SCHEMBL2392257 | 0.88 | ICMT (0.54) | ICMTPARP1SLC9A1DCLRE1BHPGDS | |
| SCHEMBL2395233 | 0.86 | ICMT (0.53) | ICMT | |
| SCHEMBL9890666 | 0.86 | PTGDR2 (0.50) | DCLRE1BKDM4ESMN1; SMN2 | |
| SCHEMBL9890766 | 0.85 | ICMT (0.45) | ICMTCHEK2PLK4DAPK3CDK1 | |
| SCHEMBL26835272 | 0.85 | ICMT (0.47) | ICMTMAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL9890765 | 0.81 | SMN1; SMN2 (0.43) | DCLRE1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885PARP1 3158/4885SLC9A1 132/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885PARP1 3158/4885SLC9A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.